Phase 2 study for people with Leukaemia

Recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 15 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 2
Sponsor Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Registry number NCT06163430
Started 26 March 2024 Today 16 October 2026 Estimated completion 30 November 2029

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Royal Adelaide Hospital Adelaide SA Recruiting
Monash Medical Centre Clayton VIC Not yet recruiting
Peter MacCallum Cancer Centre Melbourne VIC Not yet recruiting
Royal Perth Hospital Perth WA Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 15 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 330

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Key Inclusion Criteria:

Inclusion Criteria include but are not limited to:

* Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2

* Have an established cytopathologically confirmed diagnosis of breakpoint cluster region::Abelson (BCR-ABL1) positive Chronic Myeloid Leukemia (CML) in Chronic Phase

* Have received treatment with at least one prior tyrosine kinase inhibitor (TKI) and have treatment failure, suboptimal response, or treatment intolerance

* Prior treatment with asciminib is allowed

* Adequate organ function, as assessed by local laboratory

Key Exclusion Criteria:

Exclusion criteria include but are not limited to:

* Systemic antineoplastic therapy (including prior TKIs, interferon-alfa, therapeutic antibodies, chemotherapy) or other experimental therapy 7 days before the first dose of MK-4208/TERN-701

* Have completed previous anticancer therapy without resolution of all associated clinically significant toxicity (to ≤ Grade 2 or baseline)

Dates on the record

Started 26 March 2024
Estimated completion 30 November 2029
Registry last updated 15 October 2026
Checked by Voxsanity 15 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 15 October 2026.
  • This page last checked by Voxsanity: 15 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.